BR0115424A - Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto - Google Patents

Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto

Info

Publication number
BR0115424A
BR0115424A BR0115424-9A BR0115424A BR0115424A BR 0115424 A BR0115424 A BR 0115424A BR 0115424 A BR0115424 A BR 0115424A BR 0115424 A BR0115424 A BR 0115424A
Authority
BR
Brazil
Prior art keywords
compound
disease
alzheimer
inhibiting
processes
Prior art date
Application number
BR0115424-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0115424A publication Critical patent/BR0115424A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
BR0115424-9A 2000-11-17 2001-11-02 Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto BR0115424A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (1)

Publication Number Publication Date
BR0115424A true BR0115424A (pt) 2003-10-21

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115424-9A BR0115424A (pt) 2000-11-17 2001-11-02 Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto

Country Status (33)

Country Link
US (1) US20040248878A1 (cg-RX-API-DMAC7.html)
EP (1) EP1353910B1 (cg-RX-API-DMAC7.html)
JP (1) JP4116431B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030045194A (cg-RX-API-DMAC7.html)
CN (2) CN101624372A (cg-RX-API-DMAC7.html)
AR (1) AR031356A1 (cg-RX-API-DMAC7.html)
AT (1) ATE362919T1 (cg-RX-API-DMAC7.html)
AU (2) AU2432102A (cg-RX-API-DMAC7.html)
BR (1) BR0115424A (cg-RX-API-DMAC7.html)
CA (1) CA2425497C (cg-RX-API-DMAC7.html)
CY (1) CY1106682T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031340A3 (cg-RX-API-DMAC7.html)
DE (1) DE60128587T2 (cg-RX-API-DMAC7.html)
DK (1) DK1353910T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3454A1 (cg-RX-API-DMAC7.html)
EA (1) EA006919B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034598A (cg-RX-API-DMAC7.html)
ES (1) ES2286162T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030385A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0301862A3 (cg-RX-API-DMAC7.html)
IL (1) IL155275A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03004250A (cg-RX-API-DMAC7.html)
MY (1) MY141607A (cg-RX-API-DMAC7.html)
NO (1) NO325217B1 (cg-RX-API-DMAC7.html)
PE (1) PE20020798A1 (cg-RX-API-DMAC7.html)
PL (1) PL211018B1 (cg-RX-API-DMAC7.html)
PT (1) PT1353910E (cg-RX-API-DMAC7.html)
SK (1) SK287794B6 (cg-RX-API-DMAC7.html)
SV (1) SV2003000741A (cg-RX-API-DMAC7.html)
TW (1) TWI235151B (cg-RX-API-DMAC7.html)
UA (1) UA77165C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002040451A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200303411B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
TWI323256B (en) 2002-12-20 2010-04-11 Glaxo Group Ltd Novel benzazepine derivatives and pharmaceutical compositions comprising said compounds
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RU2404968C2 (ru) 2005-04-08 2010-11-27 Дайити Санкио Компани, Лимитед Пиридилдиметилсульфоновое производное
US8258302B2 (en) 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP2987496B1 (en) 2013-04-19 2018-08-08 National University Corporation Okayama University Treatment agent for cognitive disorders, induced by amyloid -protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
EP3242666B9 (en) 2015-01-06 2024-12-25 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
KR20230005163A (ko) 2020-03-26 2023-01-09 씨젠 인크. 다발성 골수종 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158355A0 (en) * 1996-12-23 2004-05-12 Elan Pharm Inc CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2002518481A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチドの放出および/またはその合成を阻害するための化合物
CA2390376A1 (en) * 1999-11-09 2001-05-17 William Leonard Scott .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis

Also Published As

Publication number Publication date
DZ3454A1 (fr) 2002-05-23
AR031356A1 (es) 2003-09-17
AU2002224321B2 (en) 2006-10-19
HUP0301862A3 (en) 2007-09-28
CY1106682T1 (el) 2012-05-23
JP4116431B2 (ja) 2008-07-09
IL155275A0 (en) 2003-11-23
NO20032215L (no) 2003-07-16
PL360991A1 (en) 2004-09-20
ZA200303411B (en) 2004-08-02
CA2425497A1 (en) 2002-05-23
NO325217B1 (no) 2008-02-25
MXPA03004250A (es) 2003-09-22
NO20032215D0 (no) 2003-05-15
EP1353910B1 (en) 2007-05-23
JP2004521084A (ja) 2004-07-15
CN1575282A (zh) 2005-02-02
SK5432003A3 (en) 2004-09-08
DK1353910T3 (da) 2007-09-10
PL211018B1 (pl) 2012-03-30
DE60128587T2 (de) 2008-01-31
MY141607A (en) 2010-05-31
HUP0301862A2 (hu) 2003-09-29
PE20020798A1 (es) 2002-09-06
WO2002040451A3 (en) 2003-08-28
AU2432102A (en) 2002-05-27
SV2003000741A (es) 2003-01-13
TWI235151B (en) 2005-07-01
EA200300579A1 (ru) 2003-12-25
WO2002040451A2 (en) 2002-05-23
EP1353910A2 (en) 2003-10-22
CZ20031340A3 (cs) 2004-06-16
HRP20030385A2 (en) 2003-08-31
EA006919B1 (ru) 2006-04-28
PT1353910E (pt) 2007-08-20
CA2425497C (en) 2010-08-17
ATE362919T1 (de) 2007-06-15
US20040248878A1 (en) 2004-12-09
SK287794B6 (sk) 2011-10-04
KR20030045194A (ko) 2003-06-09
DE60128587D1 (de) 2007-07-05
UA77165C2 (en) 2006-11-15
ES2286162T3 (es) 2007-12-01
CN101624372A (zh) 2010-01-13
CN100516047C (zh) 2009-07-22
ECSP034598A (es) 2003-06-25

Similar Documents

Publication Publication Date Title
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BR9807876A (pt) Compostos heterocìclicos e seu uso para inibição de peptìdeo beta-amilóide
BR9713404A (pt) ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos.
NO992368L (no) FremgangsmÕter og forbindelser til inhibering av <beta>-amyloidfrigivning og/eller dets syntese
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR0213139A (pt) Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
EP1093372A4 (en) CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF INHIBITING PEPTIDE RELEASE $ g (b) -AMYLOID AND / OR ITS SYNTHESIS USING THE SAME
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
EA199700151A1 (ru) Композиция для чрескожного введения

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 223/16, A61K 31/55, A61P 25/28

Ipc: C07D 223/00 (2006.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.